X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs FRESENIUS KABI ONCO. - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE FRESENIUS KABI ONCO. CADILA HEALTHCARE/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 32.4 22.1 146.4% View Chart
P/BV x 6.4 3.1 206.2% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 CADILA HEALTHCARE   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
FRESENIUS KABI ONCO.
Mar-13
CADILA HEALTHCARE/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs460176 261.4%   
Low Rs30579 388.5%   
Sales per share (Unadj.) Rs92.137.7 244.4%  
Earnings per share (Unadj.) Rs14.85.1 290.9%  
Cash flow per share (Unadj.) Rs18.56.7 274.9%  
Dividends per share (Unadj.) Rs3.200-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs68.042.5 159.8%  
Shares outstanding (eoy) m1,023.74158.23 647.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.23.4 123.0%   
Avg P/E ratio x25.825.0 103.3%  
P/CF ratio (eoy) x20.718.9 109.4%  
Price / Book Value ratio x5.63.0 188.1%  
Dividend payout %21.60-   
Avg Mkt Cap Rs m391,58120,135 1,944.8%   
No. of employees `00016.91.2 1,463.1%   
Total wages/salary Rs m15,002703 2,133.4%   
Avg. sales/employee Rs Th5,594.55,176.2 108.1%   
Avg. wages/employee Rs Th890.1610.4 145.8%   
Avg. net profit/employee Rs Th899.9699.6 128.6%   
INCOME DATA
Net Sales Rs m94,2955,963 1,581.3%  
Other income Rs m1,28618 7,144.4%   
Total revenues Rs m95,5815,981 1,598.1%   
Gross profit Rs m19,0361,430 1,331.1%  
Depreciation Rs m3,750258 1,454.1%   
Interest Rs m450-26 -1,730.8%   
Profit before tax Rs m16,1221,216 1,325.6%   
Minority Interest Rs m3380-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3-68 4.4%   
Tax Rs m1,289342 376.7%   
Profit after tax Rs m15,168806 1,882.1%  
Gross profit margin %20.224.0 84.2%  
Effective tax rate %8.028.1 28.4%   
Net profit margin %16.113.5 119.0%  
BALANCE SHEET DATA
Current assets Rs m60,2235,102 1,180.5%   
Current liabilities Rs m53,0582,385 2,224.3%   
Net working cap to sales %7.645.6 16.7%  
Current ratio x1.12.1 53.1%  
Inventory Days Days70150 46.5%  
Debtors Days Days88113 77.8%  
Net fixed assets Rs m72,9845,148 1,417.7%   
Share capital Rs m1,024158 647.3%   
"Free" reserves Rs m68,5766,556 1,046.1%   
Net worth Rs m69,6006,732 1,033.9%   
Long term debt Rs m24,684952 2,592.3%   
Total assets Rs m152,20710,388 1,465.2%  
Interest coverage x36.8-45.8 -80.4%   
Debt to equity ratio x0.40.1 250.7%  
Sales to assets ratio x0.60.6 107.9%   
Return on assets %10.37.5 136.7%  
Return on equity %21.812.0 182.0%  
Return on capital %17.914.6 122.8%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m21,2805,298 401.7%   
Fx outflow Rs m10,8741,772 613.6%   
Net fx Rs m10,4063,525 295.2%   
CASH FLOW
From Operations Rs m13,4951,274 1,059.2%  
From Investments Rs m-29,103-1,204 2,416.8%  
From Financial Activity Rs m23,158-196 -11,809.3%  
Net Cashflow Rs m7,556-126 -5,982.6%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 8.3 0.3 2,766.7%  
FIIs % 5.9 9.6 61.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 9.1 120.9%  
Shareholders   44,069 42,599 103.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  WYETH LTD  ABBOTT INDIA  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Positive Note; Apollo Micro Systems IPO Lists at 74% Premium(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the energy sector and IT sector witnessing maximum buying interest.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jan 22, 2018 01:25 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS